The emerging function of N6-methyladenosine and its regulators in endometrial cancer; Current knowledge and prospect

被引：0

作者：

Rabiei, Maryam ^{[1
]}

Ghalandarpoor-Attar, Seyedeh Mojgan ^{[2
]}

Ghalandarpoor-Attar, Seyedeh Noushin ^{[3
]}

Nurzadeh, Maryam ^{[4
]}

机构：

[1] Univ Tehran Med Sci, Obstet & Gynecol Dept, Tehran, Iran

[2] Univ Tehran Med Sci, Baharloo Hosp, Obstet & Gynecol Dept, Tehran, Iran

[3] Baqiyatallah Univ Med Sci, Baqiyatallah Hosp, Obstet & Gynecol Dept, Tehran, Iran

[4] Univ Tehran Med Sci, Shariati Hosp, Fetomaternal Dept, Tehran, Iran

来源：

HUMAN GENE | 2023年 / 38卷

关键词：

Endometrial cancer; Epigenetic; N6-methyladenosine; RNA metabolism; MESSENGER-RNA METHYLATION; CELL-PROLIFERATION; EXPRESSION; TUMORIGENICITY; PATHWAY; GENE;

D O I：

10.1016/j.humgen.2023.201232

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

N6-methyladenosine (m6A) is an epigenetic modification of RNA that was first discovered in mRNA in the 1970s. The principal contributors to RNA methylation modification are methyltransferases, demethylases, and binding proteins. M6A as the most studied RNA modification is crucial to the onset and progression of a wide range of diseases, including malignant tumors. This particular posttranscriptional alteration of RNA is both dynamic and reversible, and it controls several aspects of RNA metabolism in eucaryons such as translation, exporting, splicing, decay, and processing. One of the three most common forms of cancer in women's reproductive organs, endometrial cancer (EC) is a devastating disease. The involvement of m6A regulators in a wide variety of EC activities has been the subject of a large number of investigations. In this study, we focus on the underlying mechanisms of m6A alterations in EC and further discuss the prospective therapeutic targets linked with m6A regulators that might be used in the treatment of cancer.

引用

页数：6

共 54 条

[1] The axis of long non-coding RNA MALAT1/miR-1-3p/CXCR4 is dysregulated in patients with diabetic neuropathy [J].